NEW YORK (GenomeWeb) – Courtagen Life Sciences reported today that it has completed the comprehensive Clinical Laboratory Evaluation Program and has received its clinical laboratory permit form the state of New York.
Courtagen — a CLIA/CAP certified company — creates tests for the diagnosis of neurological disorders, primarily using next-generation DNA sequencing, bioinformatics, and clinical interpretation. These tests are designed to help physicians reveal the linkages between the genotypes and phenotypes of various neurological diseases, the company said in a statement.
"Obtaining the New York state license is an important achievement for Courtagen, and we're very proud our operation has passed the rigorous New York inspection and approval process," Courtagen CEO Brian McKernan said in a statement. The company can now offer its testing in all 50 states.
The company's full catalog of next-generation sequencing test panels will now be available in New York, including eipSEEK tests for epilepsy and seizure disorders; devSEEK and devACT tests for developmental delay, intellectual disability, and autism spectrum disorders; nucSEEK and mtSEEK tests for mitochondrial disorders; and lysoSEEK testing for lysosomal storage disorders. Courtagen's menu also includes the rxSEEK epilepsy tests to evaluate how a patient may metabolize anti-epileptic drugs.